BioCentury
ARTICLE | Clinical News

HaMPCs: Interim Phase IIb data

April 20, 2015 7:00 AM UTC

Interim data from 24 evaluable patients with OA of the knee in a single-blind, Chinese Phase IIb trial showed that 2 intra-articular injections of ReJoin given 3 weeks apart significantly reduced WOMA...